Chugai 3Q FY18 (YE Dec'18) Results - First Glance
Key highlights Continued brisk export of Actemra (+10.8% to ¥19.5b) and Alecensa (+95.7% to ¥9.2b) to Roche drove Chugai’s 3Q FY18e sales (+4.8% to...
411 Views
As Expected, USFDA Approves Hemlibra for Hemophilia A in Patients Without Inhibitors
Non-inhibitor patients constitute ~80-90% of the total hemophilia A population size Consequently, Hemlibra’s (emicizumab, in-house, US Launch -Nov...
321 Views
6-Months Looks to Be the Sweet Spot for Mean Revision in Japan....
It is no surprise to most that Japan is a mean-reverting market. Very few names experience long-term price runs like we see in other market. We...
400 Views
Japan Pharma: Core Coverage Investment Thesis and Valuations (III/III)
Takeda Pharmaceutical (4502 JP), Astellas Pharma (4503 JP), Daiichi Sankyo (4568 JP), Eisai Co Ltd (4523 JP), Otsuka Holdings (4578 JP), Chugai...
316 Views
Japan Pharma: Core Coverage Investment Thesis and Valuations (II/III)
Takeda Pharmaceutical (4502 JP), Astellas Pharma (4503 JP), Daiichi Sankyo (4568 JP), Eisai Co Ltd (4523 JP), Otsuka Holdings (4578 JP), Chugai...
285 Views